title: Photodynamic therapy; a comparison with other immunomodulatory treatments of adjuvant-enhanced arthritis in MRL-lpr mice.
abstract: Although numerous experimental immunomodulatory regimens have been reported to be effective in the treatment of rheumatoid arthritis, they also produce undesirable side effects. An alternative specific modality of localized treatment is photodynamic therapy (PDT). In this study we treated 13-week-old MRL-lpr mice whose spontaneous arthritis was enhanced by intradermal injection of Freund's complete adjuvant (FCA). One group received transcutaneous photodynamic therapy at days 0, 10, and 20, following the FCA injection. The other groups were injected with 1 mg/kg per day indomethacin, 40 mg/kg per day cyclosporin A (CsA), or treated with 3 Gy sublethal whole body irradiation (WBI). The development of swelling was monitored for 1 month, at which time proteinuria, lymphadenopathy and the histopathology of the joints and kidneys were assessed. The results demonstrated that PDT and the conventional treatments significantly ameliorated swelling of the hindlimbs from 70% in the untreated FCA-injected animals to below the 19% level characteristic of the unmanipulated control. Histological examination showed a reduction in pannus formation, and cartilage and bone destruction, the characteristics of adjuvant-enhanced arthritis. PDT did not affect the survival rate, lymphoproliferation, or proteinuria of the treated animals. However, indomethacin increased proteinuria, and was less effective in preventing cartilage and bone destruction. Furthermore, lower doses of CsA and WBI exacerbated arthritis activity. These results indicate that photodynamic therapy can inhibit the development of adjuvant-enhanced arthritis in MRL-lpr mice with similar effectiveness to the conventional treatments, but without their negative side effects.
authors.affiliation: Department of Oral Biology, Faculty of Dentistry, University of British Columbia, Vancouver, Canada.
authors.forename: L G
authors.initials: LG
authors.lastname: Ratkay
authors.forename: R K
authors.initials: RK
authors.lastname: Chowdhary
authors.forename: H C
authors.initials: HC
authors.lastname: Neyndorff
authors.forename: J
authors.initials: J
authors.lastname: Tonzetich
authors.forename: J D
authors.initials: JD
authors.lastname: Waterfield
authors.forename: J G
authors.initials: JG
authors.lastname: Levy
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D016572:Cyclosporine / Q000627:therapeutic use; D005720:Gamma Rays / Q000627:therapeutic use; D006614:Hindlimb / Q000473:pathology; D007213:Indomethacin / Q000627:therapeutic use; D007596:Joints / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D010778:Photochemotherapy; D011166:Porphyrins / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
chemical_list: D011166:Porphyrins; D011838:Radiation-Sensitizing Agents; C504224:benzoporphyrin D; D016572:Cyclosporine; D007213:Indomethacin